JP2022512156A5 - - Google Patents
Info
- Publication number
- JP2022512156A5 JP2022512156A5 JP2021532487A JP2021532487A JP2022512156A5 JP 2022512156 A5 JP2022512156 A5 JP 2022512156A5 JP 2021532487 A JP2021532487 A JP 2021532487A JP 2021532487 A JP2021532487 A JP 2021532487A JP 2022512156 A5 JP2022512156 A5 JP 2022512156A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025086518A JP2025116052A (ja) | 2018-12-10 | 2025-05-23 | メチオニンアデノシルトランスフェラーゼ２ａインヒビターとしての２－オキソキナゾリン誘導体 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862777715P | 2018-12-10 | 2018-12-10 | |
| US62/777,715 | 2018-12-10 | ||
| US201962835853P | 2019-04-18 | 2019-04-18 | |
| US62/835,853 | 2019-04-18 | ||
| US201962883945P | 2019-08-07 | 2019-08-07 | |
| US62/883,945 | 2019-08-07 | ||
| PCT/US2019/065260 WO2020123395A1 (en) | 2018-12-10 | 2019-12-09 | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025086518A Division JP2025116052A (ja) | 2018-12-10 | 2025-05-23 | メチオニンアデノシルトランスフェラーゼ２ａインヒビターとしての２－オキソキナゾリン誘導体 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022512156A JP2022512156A (ja) | 2022-02-02 |
| JPWO2020123395A5 JPWO2020123395A5 (https=) | 2022-12-16 |
| JP2022512156A5 true JP2022512156A5 (https=) | 2022-12-16 |
| JP7688578B2 JP7688578B2 (ja) | 2025-06-04 |
Family
ID=69138003
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021532487A Active JP7688578B2 (ja) | 2018-12-10 | 2019-12-09 | メチオニンアデノシルトランスフェラーゼ２ａインヒビターとしての２－オキソキナゾリン誘導体 |
| JP2025086518A Pending JP2025116052A (ja) | 2018-12-10 | 2025-05-23 | メチオニンアデノシルトランスフェラーゼ２ａインヒビターとしての２－オキソキナゾリン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025086518A Pending JP2025116052A (ja) | 2018-12-10 | 2025-05-23 | メチオニンアデノシルトランスフェラーゼ２ａインヒビターとしての２－オキソキナゾリン誘導体 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US12503467B2 (https=) |
| EP (1) | EP3894396A1 (https=) |
| JP (2) | JP7688578B2 (https=) |
| KR (1) | KR20210103498A (https=) |
| CN (2) | CN119528824A (https=) |
| AU (1) | AU2019395338B2 (https=) |
| BR (1) | BR112021010842A2 (https=) |
| CA (1) | CA3121236A1 (https=) |
| CL (1) | CL2021001508A1 (https=) |
| CO (1) | CO2021008895A2 (https=) |
| IL (1) | IL283743A (https=) |
| MA (1) | MA54452A (https=) |
| MX (1) | MX2021006841A (https=) |
| PH (1) | PH12021551274A1 (https=) |
| SG (1) | SG11202105469YA (https=) |
| TW (1) | TWI863945B (https=) |
| WO (1) | WO2020123395A1 (https=) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020123395A1 (en) | 2018-12-10 | 2020-06-18 | Ideaya Biosciences, Inc. | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors |
| US12398140B2 (en) | 2019-02-13 | 2025-08-26 | Ptc Therapeutics, Inc. | Substituted pyrrolo [2,3-d]pyrimidines for treating familial dysautonomia |
| EA202192170A1 (ru) | 2019-02-13 | 2021-11-15 | ПиТиСи ТЕРАПЬЮТИКС, ИНК. | ТИЕНО[3,2-b]ПИРИДИН-7-АМИНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ЛЕЧЕНИЯ СЕМЕЙНОЙ ВЕГЕТО-СОСУДИСТОЙ ДИСТОНИИ |
| CN115485025A (zh) * | 2020-02-28 | 2022-12-16 | 雷密克斯医疗公司 | 用于调节剪接的化合物和方法 |
| US20240208965A1 (en) * | 2020-06-10 | 2024-06-27 | Ideaya Biosciences, Inc. | Heteroaryl alkylene substituted 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors |
| CR20220644A (es) * | 2020-06-22 | 2023-02-17 | Hoffmann La Roche | Derivados de sulfona |
| WO2021259815A1 (en) * | 2020-06-22 | 2021-12-30 | F. Hoffmann-La Roche Ag | Amidopyrimidone derivatives |
| WO2021254529A1 (zh) * | 2020-07-14 | 2021-12-23 | 江苏先声药业有限公司 | 双环类化合物 |
| WO2022056307A1 (en) | 2020-09-11 | 2022-03-17 | Mirati Therapeutics, Inc. | Crystalline forms of a kras g12c inhibitor |
| CN115960099A (zh) * | 2020-09-24 | 2023-04-14 | 上海凌达生物医药有限公司 | 一类芳环或芳基杂环并吡啶酮类化合物、药物组合物及其应用 |
| CN116507624A (zh) | 2020-11-20 | 2023-07-28 | 美国安进公司 | 制备7-氯-6-氟-1-(2-异丙基-4-甲基吡啶-3-基)吡啶并f[2,3-d]嘧啶-2,4(1h,3h)-二酮的方法 |
| WO2022132200A1 (en) * | 2020-12-15 | 2022-06-23 | Mirati Therapeutics, Inc. | Azaquinazoline pan-kras inhibitors |
| EP4262803A4 (en) | 2020-12-16 | 2025-03-12 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| WO2022143864A1 (zh) | 2020-12-31 | 2022-07-07 | 江苏先声药业有限公司 | 三环类化合物及用途 |
| CN115141202A (zh) * | 2021-03-29 | 2022-10-04 | 武汉人福创新药物研发中心有限公司 | 嘧啶并吡嗪酮化合物及其用途 |
| WO2022222911A1 (zh) * | 2021-04-19 | 2022-10-27 | 武汉人福创新药物研发中心有限公司 | 嘧啶酮化合物及其用途 |
| CN117295734A (zh) * | 2021-04-30 | 2023-12-26 | 赛诺哈勃药业（成都）有限公司 | 甲硫氨酸腺苷转移酶抑制剂、其制备方法及应用 |
| EP4347569A4 (en) * | 2021-06-02 | 2025-03-26 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a type ii prmt inhibitor |
| US20240269143A1 (en) * | 2021-06-02 | 2024-08-15 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and type i prmt inhibitor |
| CN117412967A (zh) * | 2021-06-02 | 2024-01-16 | 南京正大天晴制药有限公司 | 蛋氨酸腺苷转移酶2a抑制剂 |
| EP4405347A1 (en) | 2021-09-24 | 2024-07-31 | Xenon Pharmaceuticals Inc. | Pyridine derivatives and their use as sodium channel activators |
| CN118434722A (zh) | 2021-10-20 | 2024-08-02 | 英矽智能科技知识产权有限公司 | 甲硫氨酸腺苷转移酶2a(mat2a)抑制剂及其用途 |
| CN118265700A (zh) * | 2021-11-09 | 2024-06-28 | 上海海雁医药科技有限公司 | 取代的萘啶酮衍生物、其药物组合物及应用 |
| WO2023086934A1 (en) * | 2021-11-12 | 2023-05-19 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a taxane |
| CN118414338A (zh) | 2021-12-21 | 2024-07-30 | 南京正大天晴制药有限公司 | 蛋氨酸腺苷转移酶2a的杂环抑制剂 |
| KR20240138099A (ko) * | 2022-01-26 | 2024-09-20 | 쑤저우 젠하우스 바이오 컴퍼니 리미티드 | Mtap 결실 암을 치료하기 위한 메티오닌 아데노실트랜스퍼라제 2a 억제제 |
| WO2023177894A1 (en) | 2022-03-18 | 2023-09-21 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and an antimetabolite agent |
| US20250221979A1 (en) | 2022-03-29 | 2025-07-10 | Shouyao Holdings (beijing) Co., Ltd. | Novel heterocyclic compound |
| GB202204913D0 (en) | 2022-04-04 | 2022-05-18 | Cambridge Entpr Ltd | antiviral therapy |
| WO2023201338A1 (en) | 2022-04-15 | 2023-10-19 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a parp inhibitor |
| EP4545531A1 (en) | 2022-06-27 | 2025-04-30 | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Tricyclic compounds and uses thereof |
| CN117430596A (zh) * | 2022-07-13 | 2024-01-23 | 上海海和药物研究开发股份有限公司 | 二并环类mat2a抑制剂及其用途 |
| JP2025533273A (ja) | 2022-10-13 | 2025-10-03 | ハンミ ファーマシューティカルズ カンパニー リミテッド | 新規なトリサイクル誘導体化合物及びその用途 |
| TW202440126A (zh) | 2022-11-30 | 2024-10-16 | 美商安進公司 | 利用ｍｔａ協作的ｐｒｍｔ５抑制劑和ｍａｔ２ａ抑制劑之癌症治療 |
| CN120693324A (zh) * | 2022-11-30 | 2025-09-23 | 艾迪亚生物科学公司 | 2-氧代喹唑啉的晶型 |
| EP4626887A1 (en) * | 2022-11-30 | 2025-10-08 | Ideaya Biosciences, Inc. | Atropisomers of mat2a inhibitors |
| WO2024118943A2 (en) * | 2022-11-30 | 2024-06-06 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a prmt5 inhibitor |
| CN117777134B (zh) * | 2022-12-19 | 2025-02-25 | 艾立康药业股份有限公司 | 作为mat2a抑制剂的多环类化合物 |
| KR20250170695A (ko) * | 2023-04-19 | 2025-12-05 | 인실리코 메디신 아이피 리미티드 | 메티오닌 아데노실트랜스퍼라제 2a(mat2a) 억제제 조합 및 이의 용도 |
| AU2024259244A1 (en) * | 2023-04-19 | 2025-10-30 | Insilico Medicine Ip Limited | CRYSTALLINE METHIONINE ADENOSYLTRANSFERASE 2a (MAT2A) INHIBITOR AND USES THEREOF |
| CN116283800B (zh) * | 2023-05-16 | 2023-07-18 | 英矽智能科技(上海)有限公司 | 氧代喹唑啉类化合物及其应用 |
| WO2024255802A1 (zh) * | 2023-06-14 | 2024-12-19 | 南京正大天晴制药有限公司 | 蛋氨酸腺苷转移酶2a杂环抑制剂的盐、晶型及其制备方法 |
| CN116478172B (zh) * | 2023-06-20 | 2023-09-05 | 英矽智能科技(上海)有限公司 | 吡咯并[3,2-d]嘧啶类化合物及其应用 |
| WO2025059579A1 (en) | 2023-09-15 | 2025-03-20 | Ideaya Biosciences, Inc. | Methods of treating mat2a related diseases |
| AU2024344078A1 (en) | 2023-09-20 | 2026-04-02 | Ideaya Biosciences, Inc. | Combination therapy with a parg inhibitor |
| WO2025072544A1 (en) | 2023-09-27 | 2025-04-03 | Ideaya Biosciences, Inc. | Sulfonamino indazole compounds as inhibitors of parg |
| WO2025166229A1 (en) | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Tricyclic amidino compounds as prmt5 inhibitors |
| WO2025166260A1 (en) | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Amide substituted tricyclic guanidino compounds as prmt5 inhibitors |
| WO2025166257A1 (en) | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Amide substituted triheterocyclic guanidino compounds as prmt5 inhibitors |
| WO2025166215A1 (en) | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Triheterocyclic guanidino compounds as prmt5 inhibitors |
| WO2025166274A1 (en) | 2024-02-02 | 2025-08-07 | Ideaya Biosciences, Inc. | Tricyclic guanidino compounds as prmt5 inhibitors |
| CN120842232A (zh) * | 2024-04-26 | 2025-10-28 | 中国科学院上海药物研究所 | 一种喹唑啉酮并五元杂环化合物及其药用组合物和用途 |
| WO2025250569A1 (en) | 2024-05-29 | 2025-12-04 | Amgen Inc. | Cancer treatments using mta-cooperative prmt5 inhibitors and mat2a inhibitors |
| CN118724899B (zh) * | 2024-07-03 | 2025-09-30 | 中国药科大学 | 2(1h)-喹喔啉酮化合物、其药物组合物及应用 |
Family Cites Families (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3202661A (en) | 1962-11-27 | 1965-08-24 | Hoffmann La Roche | Substituted 3-amino 4-phenyl quinolones |
| US4096144A (en) | 1970-12-08 | 1978-06-20 | Sumitomo Chemical Company, Limited | Process for preparing quinazolinone derivatives and their 2-(N-mono-substituted amino)-phenyl ketone intermediate derivatives |
| JPS5761758B2 (https=) | 1974-01-11 | 1982-12-25 | Hisamitsu Pharmaceutical Co | |
| WO1994007498A1 (fr) | 1992-10-07 | 1994-04-14 | Sumitomo Pharmaceuticals Company, Limited | Composition pharmaceutique utilisee pour inhiber la production des facteurs de necrose tumorale |
| EP0759454B1 (en) | 1994-05-11 | 2002-03-06 | Asahi Kasei Kabushiki Kaisha | para-ORIENTED AROMATIC POLYAMIDE MOLDING AND PROCESS FOR PRODUCING THE SAME |
| US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
| NZ322197A (en) | 1995-11-21 | 1999-02-25 | Yamanouchi Pharma Co Ltd | Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof |
| TW504504B (en) | 1996-11-26 | 2002-10-01 | Bristol Myers Squibb Co | 4-aryl-3-hydroxyquinolin-2-one derivatives as ion channel modulators |
| CA2301549A1 (en) | 1997-08-28 | 1999-03-04 | Piyasena Hewawasam | 4-aryl-3-aminoquinoline-2-one derivatives as potassium channel modulators |
| PA8539401A1 (es) | 2001-02-14 | 2002-10-28 | Warner Lambert Co | Quinazolinas como inhibidores de mmp-13 |
| AR038658A1 (es) | 2001-06-15 | 2005-01-26 | Novartis Ag | Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento |
| US7098332B2 (en) | 2002-12-20 | 2006-08-29 | Hoffmann-La Roche Inc. | 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones |
| WO2004065542A2 (en) | 2002-12-30 | 2004-08-05 | Exelixis, Inc. | MAT2As AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| WO2005020885A2 (en) | 2003-05-21 | 2005-03-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
| US7049309B2 (en) | 2003-10-14 | 2006-05-23 | Bristol-Myers Squibb Company | 3-Thia-4-arylquinolin-2-one potassium channel modulators |
| US8338435B2 (en) | 2006-07-20 | 2012-12-25 | Gilead Sciences, Inc. | Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections |
| ES2532277T3 (es) | 2006-11-22 | 2015-03-25 | Sumitomo Chemical Company, Limited | Derivados de quinazolina capaces de inhibir la señalización de citoquinina |
| US7928111B2 (en) | 2007-06-08 | 2011-04-19 | Senomyx, Inc. | Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors |
| EP2266984A1 (en) | 2009-06-26 | 2010-12-29 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Pyrido[2,3-d]pyrimidines as Wnt antagonists for treatment of cancer and arthritis |
| CN101671336B (zh) | 2009-09-23 | 2013-11-13 | 辽宁利锋科技开发有限公司 | 芳杂环并嘧啶衍生物和类似物及其制备方法和用途 |
| EP2534153B2 (en) | 2010-02-12 | 2024-05-22 | Pfizer Inc. | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
| US8835458B2 (en) * | 2010-08-31 | 2014-09-16 | Hanmi Science Co., Ltd | Quinoline or quinazoline derivatives with apoptosis inducing activity on cells |
| MX344772B (es) | 2011-01-28 | 2017-01-06 | Univ Kentucky Res Found | Analogos de estilbeno y metodos para tratar cancer. |
| EP2721179A4 (en) | 2011-06-16 | 2014-10-01 | Caris Life Sciences Luxembourg Holdings S A R L | BIOMARKER COMPOSITIONS AND METHOD THEREFOR |
| HK1199028A1 (en) | 2011-09-30 | 2015-06-19 | Kineta, Inc. | Anti-viral compounds |
| BR112014015549A8 (pt) * | 2011-12-22 | 2017-07-04 | Hoffmann La Roche | composto, método de inibição da atividade pak1, método para o tratamento, processo, composição, utilização de um composto e invenção |
| CN102816197B (zh) | 2012-08-24 | 2015-04-29 | 四川大学华西医院 | 一种新的嘧啶并嘧啶类核苷类似物、制备方法及其形成的超分子结构和应用 |
| JP6464139B2 (ja) | 2013-03-14 | 2019-02-06 | コンバージーン・リミテッド・ライアビリティ・カンパニーＣｏｎｖｅｒｇｅｎｅ Ｌｌｃ | ブロモドメイン含有タンパク質の阻害のための方法および組成物 |
| CN108601752A (zh) | 2015-12-03 | 2018-09-28 | 安吉奥斯医药品有限公司 | 用于治疗mtap缺失型癌症的mat2a抑制剂 |
| EP3484854B1 (en) | 2016-07-18 | 2021-01-20 | National Institute Of Biological Sciences, Beijing | Apoptosis inhibitors |
| CR20190157A (es) * | 2016-08-31 | 2019-08-13 | Agios Pharmaceuticals Inc | Inhibidores de procesos metabólicos celulares |
| SG11201901775SA (en) | 2016-09-02 | 2019-03-28 | Futurevault Inc | Real-time document filtering systems and methods |
| WO2018119183A2 (en) | 2016-12-22 | 2018-06-28 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| EA201992781A1 (ru) | 2017-05-22 | 2020-04-01 | Эмджен Инк. | Ингибиторы g12c kras и способы их применения |
| WO2018215798A1 (en) * | 2017-05-26 | 2018-11-29 | Cancer Research Technology Limited | 2-quinolone derived inhibitors of bcl6 |
| WO2018221433A1 (ja) | 2017-05-29 | 2018-12-06 | 第一三共株式会社 | ヘテロアリールアミン誘導体 |
| MA50077A (fr) | 2017-09-08 | 2020-07-15 | Amgen Inc | Inhibiteurs de kras g12c et leurs procédés d'utilisation |
| UA127059C2 (uk) | 2018-03-30 | 2023-03-29 | Ле Лаборатуар Сервьє | Гетеробіциклічні інгібітори mat2a і способи використання для лікування злоякісної пухлини |
| WO2019213516A1 (en) * | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| ES3060664T3 (en) * | 2018-06-12 | 2026-03-27 | Amgen Inc | Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer |
| GB2575490A (en) | 2018-07-12 | 2020-01-15 | Recordati Ind Chimica E Farmaceutica Spa | P2X3 receptor antagonists |
| US11376256B2 (en) | 2018-07-19 | 2022-07-05 | Agency For Science, Technology And Research | Method of treating a methionine-dependent cancer |
| AU2019388998A1 (en) * | 2018-11-29 | 2021-06-03 | Araxes Pharma Llc | Compounds and methods of use thereof for treatment of cancer |
| WO2020123395A1 (en) | 2018-12-10 | 2020-06-18 | Ideaya Biosciences, Inc. | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors |
| MA54608B1 (fr) | 2018-12-27 | 2023-02-28 | Servier Lab | Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer |
| MX2021007833A (es) | 2018-12-27 | 2021-10-26 | Les Laboratoires Servier Sas | Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer. |
| WO2021252679A1 (en) | 2020-06-10 | 2021-12-16 | Ideaya Biosciences, Inc. | 2-aminoquinazolinone derivatives as methionine adenosyltransferase 2a inhibitors |
| US20230227409A1 (en) | 2020-06-10 | 2023-07-20 | Ideaya Biosciences, Inc. | Quinolinone derivatives as methionine adenosyltransferase 2a inhibitors |
| WO2021252680A1 (en) | 2020-06-10 | 2021-12-16 | Ideaya Biosciences, Inc. | 4-arylquinazoline derivatives as methionine adenosyltransferase 2a inhibitors |
| US20240208965A1 (en) | 2020-06-10 | 2024-06-27 | Ideaya Biosciences, Inc. | Heteroaryl alkylene substituted 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors |
| WO2022036067A1 (en) | 2020-08-12 | 2022-02-17 | Servier Pharmaceuticals, Llc | Combination therapies for use in treating cancer |
| JP7671302B2 (ja) | 2020-09-11 | 2025-05-01 | 株式会社半導体エネルギー研究所 | 表示装置、表示モジュール、及び電子機器 |
| EP4347569A4 (en) | 2021-06-02 | 2025-03-26 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a type ii prmt inhibitor |
| WO2023086934A1 (en) | 2021-11-12 | 2023-05-19 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a taxane |
| US20250243188A1 (en) | 2022-04-08 | 2025-07-31 | Ideaya Biosciences, Inc. | Methionine adenosyltranserase 2a inhibitors |
| WO2023201338A1 (en) | 2022-04-15 | 2023-10-19 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a parp inhibitor |
| EP4626887A1 (en) | 2022-11-30 | 2025-10-08 | Ideaya Biosciences, Inc. | Atropisomers of mat2a inhibitors |
-
2019
- 2019-12-09 WO PCT/US2019/065260 patent/WO2020123395A1/en not_active Ceased
- 2019-12-09 SG SG11202105469YA patent/SG11202105469YA/en unknown
- 2019-12-09 CA CA3121236A patent/CA3121236A1/en active Pending
- 2019-12-09 AU AU2019395338A patent/AU2019395338B2/en active Active
- 2019-12-09 BR BR112021010842-4A patent/BR112021010842A2/pt unknown
- 2019-12-09 CN CN202411684986.9A patent/CN119528824A/zh active Pending
- 2019-12-09 US US17/311,873 patent/US12503467B2/en active Active
- 2019-12-09 KR KR1020217021424A patent/KR20210103498A/ko active Pending
- 2019-12-09 MX MX2021006841A patent/MX2021006841A/es unknown
- 2019-12-09 CN CN201980081299.9A patent/CN113166078B/zh active Active
- 2019-12-09 EP EP19832505.2A patent/EP3894396A1/en active Pending
- 2019-12-09 JP JP2021532487A patent/JP7688578B2/ja active Active
- 2019-12-09 MA MA054452A patent/MA54452A/fr unknown
- 2019-12-10 TW TW108145188A patent/TWI863945B/zh active
-
2021
- 2021-02-12 US US17/175,579 patent/US11084798B1/en active Active
- 2021-02-12 US US17/175,578 patent/US11046691B1/en active Active
- 2021-02-12 US US17/175,581 patent/US11130759B1/en active Active
- 2021-05-31 PH PH12021551274A patent/PH12021551274A1/en unknown
- 2021-06-06 IL IL283743A patent/IL283743A/en unknown
- 2021-06-09 CL CL2021001508A patent/CL2021001508A1/es unknown
- 2021-07-06 CO CONC2021/0008895A patent/CO2021008895A2/es unknown
-
2025
- 2025-05-23 JP JP2025086518A patent/JP2025116052A/ja active Pending